Dr. Robert Spiegel, who in 2016 joined Vidac’s board as an observer, is the former CMO of Schering Plough Corporation where he served as SVP worldwide clinical development and participated in over 30 NDAs. He is now an Associate Professor at Weill Cornell Medical School and serves as an Advisor to Warburg Pincus. He is a member of the Board of several private and public biotech companies and serves as the President of Spiegel Consulting LLC. He is a graduate of Yale University (B.A.) and University of Pennsylvania (M.D.) and completed his medical training as a Research Associate at the National Cancer Institute, NIH.
Prof. Max Herzberg, the Founder and Chairperson of the Board of Vidac Pharma, is a renowned scientist and entrepreneur and one of the founding fathers of the Israel life sciences industry. Prof. Herzberg founded Orgenics and the EagerBio Group, is the co-founder of PixCell, and served as chairperson of several Israeli biotechnology companies and as chairperson of the European Molecular Biology Laboratory Enterprise Management (Heidelberg, Germany). Prof. Herzberg holds a Ph.D. in Molecular Biology from the Weizmann Institute of Science.
Dr. Shmuel Cabilly, holds a PhD in Immunology from the Hebrew university (1980). He spent four years in the US as a post-doctoral fellow heading a joint project of the City of Hope Research Institute and Genentech where he developed a new breakthrough technology for recombinant antibody production. This invention was patented worldwide. Today there are already more than 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more. Dr Cabilly was also a co-founder and a chief scientist of Life technology Israel (formerly Ethrog Biotechnology) which was acquired by Invitrogen corp. (today Life technology). Dr. Cabilly is now an investor and a director of several companies.
Ed Saltzman is President and Founder of Defined Health, a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment sectors, has joined Vidac’s Board in 2016. Leveraging 25+ years of experience consulting for biopharma companies, he provides guidance to Defined Health’s senior project leadership who work with clients across multiple therapeutic areas. Ed is an in demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that go on to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field. He notably coined the term “Proof of Relevance,” to describe indisputable demonstration of clinical and economic value in drug development. Ed is a graduate of New York University. He is an advisor to the Israeal Biotech Fund, and a member of the Licensing Executives Society (LES) and the New York Pharma Forum, and is a recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector.
Dr. Livia Theodor, a molecular genetics scientist and a Master of Business Administration, is a partner and lead scientist of Mivtach-Shamir Technologies venture fund. She is also the CEO of MyCells Israel, a company in the field of cell regeneration from autologous blood. Previously, Dr. Theodor was the CEO and co-founder of Taburit, Israel’s major cord blood bank and the director of the gastroenterology research laboratory and the director of the onco-diagnostics laboratory at the Sheba Medical Center, Tel Hashomer Hospital, Israel. Livia was also a Member of the Center of Incubators for Technological Initiative Committee, Ministry of Industry, Trade & Labor, State of Israel.